Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1806 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	I
2	2	119THCONGRESS
3	3	1
4	4	STSESSION H. R. 1806
5	5	To provide for research and education with respect to triple-negative breast
6	6	cancer, and for other purposes.
7	7	IN THE HOUSE OF REPRESENTATIVES
8	8	MARCH3, 2025
9	9	Mr. M
10	10	ORELLE(for himself and Mr. BACON) introduced the following bill;
11	11	which was referred to the Committee on Energy and Commerce
12	12	A BILL
13	13	To provide for research and education with respect to triple-
14	14	negative breast cancer, and for other purposes.
15	15	Be it enacted by the Senate and House of Representa-1
16	16	tives of the United States of America in Congress assembled, 2
17	17	SECTION 1. SHORT TITLE. 3
18	18	This Act may be cited as the ‘‘Triple-Negative Breast 4
19	19	Cancer Research and Education Act of 2025’’. 5
20	20	SEC. 2. FINDINGS. 6
21	21	Congress finds as follows: 7
22	22	(1) Breast cancer accounts for 1 in 4 cancer di-8
23	23	agnoses among women in this country. 9
24	24	VerDate Sep 11 2014 00:50 Mar 18, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H1806.IH H1806
25	25	ssavage on LAPJG3WLY3PROD with BILLS 2
26	26	•HR 1806 IH
27	27	(2) The survival rate for breast cancer has in-1
28	28	creased to 90 percent for White women and 78 per-2
29	29	cent for African-American women. 3
30	30	(3) African-American women are more likely to 4
31	31	be diagnosed with larger tumors and more advanced 5
32	32	stages of breast cancer despite a lower incidence 6
33	33	rate. 7
34	34	(4) Early detection for breast cancer increases 8
35	35	survival rates for breast cancer, as evidenced by a 5- 9
36	36	year relative survival rate of 98 percent for breast 10
37	37	cancers that are discovered before the cancer 11
38	38	spreads beyond the breast, compared to 23 percent 12
39	39	for stage IV breast cancers. 13
40	40	(5) Triple-negative breast cancer is a term used 14
41	41	to describe breast cancers whose cells do not have 15
42	42	estrogen receptors and progesterone receptors, and 16
43	43	do not have an excess of the HER2 protein on their 17
44	44	sources. 18
45	45	(6) It is estimated that between 10 and 20 per-19
46	46	cent of female breast cancer patients are diagnosed 20
47	47	with triple-negative breast cancer, and studies indi-21
48	48	cate the prevalence of triple-negative breast cancer is 22
49	49	much higher. 23
50	50	VerDate Sep 11 2014 00:50 Mar 18, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H1806.IH H1806
51	51	ssavage on LAPJG3WLY3PROD with BILLS 3
52	52	•HR 1806 IH
53	53	(7) Triple-negative breast cancer most com-1
54	54	monly affects African-American women, followed by 2
55	55	Hispanic women. 3
56	56	(8) Triple-negative breast cancer is a very ag-4
57	57	gressive form of cancer which affects women under 5
58	58	the age of 50 across all racial and socioeconomic 6
59	59	backgrounds. 7
60	60	(9) African-American women are 3 times more 8
61	61	likely to develop triple-negative breast cancer than 9
62	62	White women. 10
63	63	(10) Triple-negative breast cancer tends to 11
64	64	grow and spread more quickly than most other types 12
65	65	of breast cancer. 13
66	66	(11) Like other forms of breast cancer, triple- 14
67	67	negative breast cancer is treated with surgery, radi-15
68	68	ation therapy, or chemotherapy. 16
69	69	(12) Early-stage detection of triple-negative 17
70	70	breast cancer is the key to survival because the 18
71	71	tumor cells lack certain receptors, and neither hor-19
72	72	mone therapy nor drugs that target these receptors 20
73	73	are effective against these cancers; therefore, early 21
74	74	detection and education is vital. 22
75	75	(13) Current research and available data do not 23
76	76	provide adequate information on— 24
77	77	VerDate Sep 11 2014 00:50 Mar 18, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H1806.IH H1806
78	78	ssavage on LAPJG3WLY3PROD with BILLS 4
79	79	•HR 1806 IH
80	80	(A) the rates of prevalence and incidence 1
81	81	of triple-negative breast cancer in African- 2
82	82	American, Hispanic, and other minority women; 3
83	83	(B) the costs associated with treating tri-4
84	84	ple-negative breast cancer; and 5
85	85	(C) the methods by which triple-negative 6
86	86	breast cancer may be prevented or cured in 7
87	87	these women. 8
88	88	SEC. 3. TRIPLE-NEGATIVE BREAST CANCER. 9
89	89	Subpart I of part C of title IV of the Public Health 10
90	90	Service Act (42 U.S.C. 285 et seq.) is amended by insert-11
91	91	ing after section 417A (42 U.S.C. 285a–7) the following: 12
92	92	‘‘SEC. 417B. TRIPLE-NEGATIVE BREAST CANCER. 13
93	93	‘‘(a) R
94	94	ESEARCH.— 14
95	95	‘‘(1) I
96	96	N GENERAL.—The Director of the Na-15
97	97	tional Institutes of Health (in this section referred 16
98	98	to as the ‘Director of NIH’) shall expand, intensify, 17
99	99	and coordinate programs for the conduct and sup-18
100	100	port of research with respect to triple-negative 19
101	101	breast cancer. 20
102	102	‘‘(2) A
103	103	DMINISTRATION.—The Director of NIH 21
104	104	shall carry out this subsection through the appro-22
105	105	priate institutes, offices, and centers of the National 23
106	106	Institutes of Health, including the Eunice Kennedy 24
107	107	Shriver National Institute of Child Health and 25
108	108	VerDate Sep 11 2014 00:50 Mar 18, 2025 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\H1806.IH H1806
109	109	ssavage on LAPJG3WLY3PROD with BILLS 5
110	110	•HR 1806 IH
111	111	Human Development, the National Institute of En-1
112	112	vironmental Health Sciences, the Office of Research 2
113	113	on Women’s Health, and the National Institute on 3
114	114	Minority Health and Health Disparities. 4
115	115	‘‘(3) C
116	116	OORDINATION OF ACTIVITIES .—The Di-5
117	117	rector of the Office of Research on Women’s Health 6
118	118	shall coordinate activities under this subsection 7
119	119	among the institutes, offices, and centers of the Na-8
120	120	tional Institutes of Health. 9
121	121	‘‘(4) A
122	122	UTHORIZATION OF APPROPRIATIONS .— 10
123	123	For the purposes of carrying out this subsection, 11
124	124	there are authorized to be appropriated such sums 12
125	125	as may be necessary for each of the fiscal years 13
126	126	2026 through 2031. 14
127	127	‘‘(b) E
128	128	DUCATION ANDDISSEMINATION OFINFORMA-15
129	129	TIONWITHRESPECT TO TRIPLE-NEGATIVEBREAST 16
130	130	C
131	131	ANCER.— 17
132	132	‘‘(1) T
133	133	RIPLE-NEGATIVE BREAST CANCER PUB -18
134	134	LIC EDUCATION PROGRAM .—The Secretary of 19
135	135	Health and Human Services, acting through the Di-20
136	136	rector of the Centers for Disease Control and Pre-21
137	137	vention, shall develop and disseminate to the public 22
138	138	information regarding triple-negative breast cancer, 23
139	139	including information on— 24
140	140	VerDate Sep 11 2014 00:50 Mar 18, 2025 Jkt 059200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\H1806.IH H1806
141	141	ssavage on LAPJG3WLY3PROD with BILLS 6
142	142	•HR 1806 IH
143	143	‘‘(A) the incidence and prevalence of triple- 1
144	144	negative breast cancer among women; 2
145	145	‘‘(B) the elevated risk for minority women 3
146	146	to develop triple-negative breast cancer; and 4
147	147	‘‘(C) the availability, as medically appro-5
148	148	priate, of a range of treatment options for 6
149	149	symptomatic triple-negative breast cancer. 7
150	150	‘‘(2) D
151	151	ISSEMINATION OF INFORMATION .—The 8
152	152	Secretary may disseminate information under para-9
153	153	graph (1) directly or through arrangements with 10
154	154	nonprofit organizations, consumer groups, institu-11
155	155	tions of higher education, Federal, State, or local 12
156	156	agencies, or the media. 13
157	157	‘‘(3) A
158	158	UTHORIZATION OF APPROPRIATIONS .— 14
159	159	For the purpose of carrying out this subsection, 15
160	160	there are authorized to be appropriated such sums 16
161	161	as may be necessary for each of the fiscal years 17
162	162	2026 through 2031. 18
163	163	‘‘(c) I
164	164	NFORMATION TO HEALTHCAREPROVIDERS 19
165	165	W
166	166	ITHRESPECT TO TRIPLE-NEGATIVEBREASTCAN-20
167	167	CER.— 21
168	168	‘‘(1) D
169	169	ISSEMINATION OF INFORMATION .—The 22
170	170	Secretary of Health and Human Services, acting 23
171	171	through the Administrator of the Health Resources 24
172	172	and Services Administration, shall develop and dis-25
173	173	VerDate Sep 11 2014 00:50 Mar 18, 2025 Jkt 059200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\H1806.IH H1806
174	174	ssavage on LAPJG3WLY3PROD with BILLS 7
175	175	•HR 1806 IH
176	176	seminate to health care providers information on tri-1
177	177	ple-negative breast cancer for the purpose of ensur-2
178	178	ing that health care providers remain informed 3
179	179	about current information on triple-negative breast 4
180	180	cancer. Such information shall include the elevated 5
181	181	risk for minority women to develop triple-negative 6
182	182	breast cancer and the range of available options for 7
183	183	the treatment of symptomatic triple-negative breast 8
184	184	cancer. 9
185	185	‘‘(2) A
186	186	UTHORIZATION OF APPROPRIATIONS .— 10
187	187	For the purpose of carrying out this subsection, 11
188	188	there are authorized to be appropriated such sums 12
189	189	as may be necessary for each of the fiscal years 13
190	190	2026 through 2031. 14
191	191	‘‘(d) D
192	192	EFINITION.—In this section, the term ‘minor-15
193	193	ity women’ means women who are members of a racial 16
194	194	and ethnic minority group, as defined in section 17
195	195	1707(g).’’. 18
196	196	Æ
197	197	VerDate Sep 11 2014 00:50 Mar 18, 2025 Jkt 059200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6301 E:\BILLS\H1806.IH H1806
198	198	ssavage on LAPJG3WLY3PROD with BILLS